Do antibody–drug conjugates increase the risk of sepsis in cancer patients? A pharmacovigilance study

Shuang Xia1,2,3, Yi-Chang Zhao1,2,3, Lin Guo1,2,3, Hui Gong1,2,3, Yi-Kun Wang1,2,3, Rui Ma1,2,3, Bi-Kui Zhang1,2,3, Yue Sheng4, Mayur Sarangdhar5,6,7, Yoshihiro Noguchi8 and Miao Yan1,2,3*

1Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China, 2International Research Center for Precision Medicine, Transformative Technology and Software Services, Hunan, China, 3Toxicology Counseling Center of Hunan Province (TCCH), Changsha, China, 4Department of Hematology, The Second Xiangya Hospital, Central South University, Changsha, China, 5Division of Biomedical Informatics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States, 6Division of Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States, 7Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States, 8Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan

Introduction: Antibody–drug conjugates (ADCs) produce unparalleled efficacy in refractory neoplasms but can also lead to serious toxicities. Although ADC-related sepsis has been reported, the clinical features are not well characterized in real-world studies.

Objective: The aim of this study was to identify the association between ADCs and sepsis using FAERS data and uncover the clinical characteristics of ADC-related sepsis.

Methods: We performed disproportionality analysis using FAERS data and compared rates of sepsis in cancer patients receiving ADCs vs. other regimens. Associations between ADCs and sepsis were assessed using reporting odds ratios (RORs) and information component (IC). For each treatment group, we detected drug interaction signals, and conducted subgroup analyses (age, gender, and regimens) and sensitivity analyses.

Results: A total of 24,618 cases were reported with ADCs between Q1, 2004 and Q3, 2021. Sepsis, septic shock, multiple organ dysfunction syndrome, and other sepsis-related toxicities were significantly associated with ADCs than other drugs in this database. Sepsis and multiple organ dysfunction syndrome have the highest safety concerns with ADCs compared with other anticancer monotherapies. Gemtuzumab ozogamicin and inotuzumab ozogamicin showed increased safety risks than other ADCs. For the top nine ADC-related sepsis, males showed higher sepsis safety concern than females (p < 0.001); however, age did not exert influence on the risk of sepsis. We identified that 973 of 2,441 (39.9%) cases had acute myeloid leukemia (AML), and 766 of 2613 (29.3%) cases on ADCs died during therapy. Time-to-onset analysis indicated ADC-related sepsis is prone to occur within a month after administration. Co-administration of ADCs with colony-stimulating factors, proton pump inhibitors, H2-receptor antagonists, or CYP3A4/
5 inhibitors showed to synergistically increase the risk of sepsis-related toxicities.

**Conclusion:** Antibody–drug conjugates may increase the risk of sepsis in cancer patients, leading to high mortality. Further studies are warranted to characterize the underlying mechanisms and design preventive measures for ADC-related sepsis.

**KEYWORDS**

antibody–drug conjugates, sepsis, pharmacovigilance, FAERS, data mining

### Introduction

Antibody–drug conjugates (ADCs) are a relatively new class of anticancer agents designed to merge the selectivity of monoclonal antibodies with cell-killing properties of chemotherapy. They are commonly described as the “Trojan horses” of therapeutic armamentarium because of their capability of directly conveying cytotoxic drug (payloads) into the tumor space, thus transforming chemotherapy into a targeted agent (Criscitiello et al., 2021). The FDA has approved 12 ADCs, which could be categorized by different kinds of payload, tubulin polymerization inhibitors (trastuzumab emtansine, enfortumab vedotin, brentuximab vedotin, polatuzumab vedotin, belantamab mafodotin, and tisotumab vedotin), DNA-damaging agents (gemtuzumab ozogamicin, inotuzumab ozogamicin, trastuzumab deruxtecan, and sacituzumab govotecan), pyrrolobenzodiazepine (loncastuximab tesirine), and truncated exotoxin (moxetumomab pasudotox). ADCs have an excellent risk-to-benefit ratio (Chau et al., 2019) in many types of neoplasms and seem suited to provide benefit for patients with treatment-refractory cancers (Drago et al., 2021). A recent study indicated that grade 3/4 anemia, neutropenia, and peripheral neuropathy were consistently reported for ADCs whose payload is monomethyl auristatin E (MMAE), thrombocytopenia and hepatic toxicity for emtansine (DM1), and ocular toxicity for monomethyl auristatin F (MMAF) (Masters et al., 2018). Another study showed that despite the use of antibodies targeting antigens abundantly and exclusively expressed on cancer cells (i.e., target cells), dose-limiting toxicities (DLTs) in normal cells/tissues are frequently reported even at suboptimal therapeutic doses (Mahalingaiah et al., 2019).

Sepsis is a condition that is associated with extremely high mortality and, for many of those who survive, severe morbidity. Cancer patients with sepsis have higher mortality rates than non-cancer patients (Hensley et al., 2019; Manjappachar et al., 2022). A recent study further indicated that septic shock in patients with hematologic malignancies is associated with a high mortality rate and poor 90-day survival compared with the control group. The World Health Organization (WHO) designated sepsis a global health priority in 2017 and adopted a resolution to improve the prevention, diagnosis, and management of sepsis (Cecconi et al., 2018).

The first case of sepsis was reported with brentuximab vedotin in 2014 (Schaefer et al., 2014). Since then, several sepsis cases have been reported with ADCs, such as enfortumab vedotin, polatuzumab vedotin, and inotuzumab ozogamicin, in clinical trials (DeAngelo et al., 2020; Sehn et al., 2020; Powles et al., 2021). A pool analysis of clinical trials showed that 28% of cancer patients who received gemtuzumab ozogamicin developed grade 3 to 4 infection, of which 16% progressed to sepsis (Koo and Baden, 2008). However, there are no reviews, meta-analyses, or large cohort studies to identify the association between sepsis and ADCs. The clinical characteristics, broad spectrum, and outcome of sepsis-related toxicities correlated with ADCs remain unknown. Herein, our pharmacovigilance study analyzes the association between ADCs and sepsis-related toxicities using data from the FDA’s Adverse Event Report System (FAERS).

### Materials and methods

**Study design and data sources**

The study protocol for our observational, retrospective, cross-sectional pharmacovigilance study of the FAERS database (evaluation of reporting of antibody–drug conjugate-associated sepsis-related toxicities) was registered on ClinicalTrials.gov, NCT05349383. AERSMine (Sarangdhar et al., 2016), a validated web-based platform that analyzes FAERS reports for AE (adverse event) association with drugs, indications, and other features including demographics, reporting period, and report source, was used to conduct this pharmacovigilance analysis. Several high-impact studies (Sarangdhar et al., 2016; Fadini et al., 2018; Fadini et al., 2019; Suarez-Almazor et al., 2019; Sarangdhar et al., 2021) have used AERSMine to analyze FAERS data, including a recent study (van Hasselt et al., 2020) which combined post-marketing data with cell line-derived transcriptomic datasets to identify a gene signature to predict the risk of cardiotoxicity with protein kinase inhibitors. Ethical approval was not required because this study was conducted by using deidentified data.
Procedures

This study included all sepsis-related toxicities in cancer patients reported between 2004 and 2021 (Q3) and classified by preferred term (PT) under sepsis (SMQ, Standardised MedDRA Query), according to the Medical Dictionary for Regulatory Activities (MedDRA 25.0; Supplementary Material S1) sepsis reports with counts > 0 were included. We used case/non-case analysis to study if sepsis was differentially reported with ADCs as compared to other drugs in the complete database. To highlight the underlying association between ADCs and sepsis, we compared the safety signals of sepsis among ADCs and other common cancer regimens, such as chemotherapy, targeted therapy, and their combinations. First, we identified relevant National Comprehensive Cancer Network (NCCN) guidelines (Supplementary Material S1), according to FDA-approved indications of ADCs. Then we extracted different cancer regimens (Supplementary Material S1) from those selected NCCN guidelines. AERSMine was used to analyze sepsis safety signals among different regimens. We used a heatmap to display the landscape of sepsis-related toxicities among anticancer therapies.

For detailed clinical features, we analyzed the sepsis frequencies by age, gender, and different ADCs regimens, and used the forest plot to visualize the difference. The outcome of ADC-related sepsis was also detected. Furthermore, a previous study showed the time-to-onset analysis method does not share the major drawback of disproportionality analysis (DPA) known as the masking effect and could be a complementary tool to detect safety signals apart from traditional DPA (Van Holle et al., 2012). Another study displayed the process of the time-to-onset analysis in detail by using the Weibull distribution (Ando et al., 2019). We detected time to onset of ADC-related sepsis leveraging FAERS raw data in this study.

Drug–drug interaction (DDI) may affect the occurrence and severity of adverse drug reactions. For instance, a higher proportion of patients reported interstitial pneumonitis for nivolumab in combination with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) vs. treatment with either drug alone (Oshima et al., 2018). Granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) is usually used to augment myeloid cell functions in cancer patients receiving chemotherapy. Previous research studies showed that granulocyte colony-stimulating factor could enhance the effect of gemtuzumab ozogamicin in acute myeloid leukemia (Leone et al., 2004) and primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin in addition to chemotherapy (Straus et al., 2020). The expert consensus on the clinical application of antibody–drug conjugates in the treatment of malignant tumors (2020 edition) of China (Professional Committee on Clinical Research of Oncology Drugs CA-CAExpert Committee for Monitoring the Clinical Application of Antitumor DrugsBreast Cancer Expert Committee of National Cancer Quality Control CenterCancer Chemotherapy Quality Control Expert Committee of Beijing Cancer Treatment Quality Control and Improvement Center, 2021) also recommended that colony-stimulating factors could be used to prevent the neutropenia associated with ADCs. So we detected the safety signal of sepsis when colony-stimulating factors were combined with ADCs in the DDI analysis. A previous research study (Zhang et al., 2022) showed that proton pump inhibitors (PPIs) interfere with the antitumor potency of HER2-targeting ADCs due to the inhibition of vacuolar H+-ATPase activity. We inferred that drugs that inhibit gastric acid secretion, such as proton pump inhibitors and H2-receptor antagonists, may alter the risk of sepsis when co-administered with ADCs. Moreover, we searched the DrugBank (Wishart et al., 2018) and found that enfentumab vedotin, brentuximab vedotin, polatuzumab vedotin, tisotumab vedotin, trastuzumab deruxtecan, and loncastuximab tesirine are mainly metabolized by the CYP3A4/5 enzyme. When the activity of the CYP3A4/5 enzyme was affected by other drugs, the metabolism process of ADCs would also be affected. So we also detected the safety signal of sepsis when ADCs were combined with proton pump inhibitors, H2-receptor antagonists, and CYP3A4/5 strong inhibitors.

Since pharmacovigilance studies based on spontaneous reporting systems can be impacted by reporting bias (Noguchi et al., 2021), we further conducted sensitivity analysis by excluding known drugs and indications which may increase susceptibility to sepsis.

Statistical analysis

In this study, two calculation indicators of disproportionality were used, the reporting odds ratio (ROR) (Rothman et al., 2004) based on the frequentist statistical method and the information component (IC) (Bate et al., 1998) based on the Bayesian statistical method used at the Uppsala Monitoring Centre (UMC). When the lower limit of the 95% credibility interval of ROR (ROR025) > 1 (Rothman et al., 2004) or the lower limit of the 95% credibility interval of IC (IC025) > 0 (Bate et al., 1998), significant adverse events were detected. Noren et al. (2013) put forward shrinkage observed-to-expected ratios to provide effective protection against spurious associations in signal detection. This adjustment calculation method was used in our analysis. These IC and ROR are standard pharmacovigilance metrics and have recently been shown to quantitate the spectrum and characteristics of immune
checkpoint inhibitor–related cardiovascular toxicity (Salem et al., 2018).

Several methods for detecting DDI have been reported (Noguchi et al., 2019); however, the omega (Ω) shrinkage observed-to-expected ratio measure (Noren et al., 2008; Noguchi et al., 2019) used by the UMC (UMC, 2016) has shown to be the most conservative in DDI signal detection (Noguchi et al., 2020). The detection criterion is the lower limit of the 95% credibility interval of Ω (Ω025 > 0 (calculation of IC, ROR, and Ω are included in Supplementary Material S1). Safety signals of sepsis-related toxicities among diverse treatment regimens were conducted using the χ² test (Bonferroni adjustment). All data analyses were performed independently by two or more authors, and all statistical analyses were performed with JMP Pro 16 (SAS Institute Inc., Cary, NC, United States) and Microsoft Excel (2021).

### Results

#### ADCs-sepsis disproportionate analysis

Our post-marketing safety signal analysis showed that sepsis and other related toxicities were significantly associated with ADCs. Sepsis (ROR025 6.55 and IC025 2.63), septic shock (ROR025 6.85 and IC025 2.71), multiple organ dysfunction syndrome (ROR025 14.77 and IC025 3.78), neutropenic sepsis (ROR025 16.34 and IC025 3.89), and bacteremia (ROR025 6.49 and IC025 2.59) were the five most common sepsis-related toxicities correlated with ADCs (Table 1). The IC values and their 95% credibility intervals over time for sepsis, septic shock, neutropenic sepsis, and multiple organ dysfunction syndrome, which are top four of the most reported sepsis-related toxicities, are shown in Figure 1.
Clinical features of sepsis-related toxicities during ADC therapies

We further analyzed the clinical characteristics of the five most common sepsis-related toxicities correlated with ADCs (Table 2). About 71.1% (1,556/2,188) of cases were reported by medical professionals, and 48.7% (1,065/2,188) of cases were reported in 2019–2021. ADC-related sepsis cases were predominantly reported largely in patients with acute myeloid leukemia (39.9% of all cases; n = 973/2,441). The co-reported toxicities’ landscape among sepsis-related toxicities shows that sepsis, septic shock, and multiple organ dysfunction syndrome not only overlap with each other but also with other serious toxicities such as veno-occlusive liver disease (Figure 2). To evaluate the onset of ADC-induced sepsis, we conducted time-to-onset analysis using a curated FAERS dataset (Khaleel et al., 2022). The β-coefficient and its 95% CI for sepsis, septic shock, and bacteremia were less than one, suggesting that the onset time of ADC-induced sepsis is the early failure type, and approximately 60% of sepsis, septic shock, and bacteremia due to ADC therapies developed within 26.6–32.3 days. However, the β and 95% CI of neutropenic sepsis include 1, and nearly 60% of patients who received ADCs would develop neutropenic sepsis within 3 weeks (Table 3; Figure 3).

We further identified that death, as an outcome, was common in patients with ADC-related sepsis. We identified that 340 of 1,177 (28.9%), 165 of 562 (29.4%), 129 of 322 (40.1%), 57 of 189 (30.1%), and 21 of 119 (17.7%) death cases were reported in patients who developed sepsis, septic shock, multiple organ dysfunction syndrome, neutropenic sepsis, and bacteremia, respectively (Figure 4). We conducted the subgroup analysis of sepsis-related toxicities according to ADC categories, gender, and age. Subgroup analysis of sepsis-related toxicities stratified by ADC categories, gender, and age revealed that both gemtuzumab ozogamicin and inotuzumab ozogamicin, with calicheamicin payload, showed higher safety concerns for sepsis than any other ADCs (Figure 5; Table 4). Males showed significantly higher safety concern for sepsis-related events than females (Figure 6, p < 0.0001). There was no significant difference for sepsis-related toxicities among different age-groups (0–14 years, 15–24 years, 25–65 years, or >65 years, p >0.05).

Sepsis signals in ADCs and other anticancer regimens

We further compared the incidence of sepsis-related toxicities across different cancer regimens (Figure 7, Figure 8). When compared with the global controls (all cancer patients) or within class (e.g., ADCs, targeted therapy, and immunotherapy), we found that ADCs presented the highest safety concern for sepsis, multiple organ dysfunction syndrome, pseudomonal sepsis, fungemia, and blood culture positive compared with any other cancer drug regimens (p <0.05). We also noted that the combination of ADCs and chemotherapy significantly increased the safety concern of septic shock, neutropenic sepsis, and bacteremia (Supplementary Material S3).

Co-administration and drug–drug interaction signal analysis

First, we analyzed the safety signal for sepsis when ADCs were co-administrated with the granulocyte colony-stimulating factor
TABLE 2 Clinical characteristics of sepsis-related toxicities correlated with ADCs.

| Characteristics                  | Sepsis   | Septic shock | Multiple organ dysfunction syndrome | Neutropenic sepsis | Bacteremia |
|----------------------------------|----------|--------------|------------------------------------|--------------------|------------|
| Total number of reporting source | 1,054    | 419          | 408                                | 193                | 114        |
| Medical staff                    | 742 (70.4) | 306 (73.0) | 281 (68.9)                         | 151 (78.2)         | 76 (66.7)  |
| Non-medical staff                | 312 (29.6) | 113 (27.0) | 127 (31.1)                         | 42 (21.8)          | 38 (33.3)  |
| Reporting year                   |          |              |                                     |                    |            |
| 2016–2021 (Q3)                   | 511 (48.5) | 230 (54.9) | 189 (46.3)                         | 80 (41.5)          | 55 (48.2)  |
| 2010–2015                        | 236 (22.4) | 86 (20.5)  | 112 (27.5)                         | 79 (40.9)          | 29 (25.4)  |
| 2004–2009                        | 307 (29.1) | 103 (24.6) | 107 (26.2)                         | 34 (17.6)          | 30 (26.3)  |
| Gender                           |          |              |                                     |                    |            |
| Male                             | 496 (54.3) | 215 (58.6) | 231 (59.4)                         | 94 (54.0)          | 52 (52.0)  |
| Female                           | 418 (45.7) | 152 (41.4) | 144 (40.6)                         | 80 (46.0)          | 48 (48.0)  |
| Data available                   | 914      | 367          | 355                                | 174                | 100        |
| Age-group, years                 |          |              |                                     |                    |            |
| 0–14                             | 26 (3.6)  | 1 (0.3)      | 22 (6.8)                           | 3 (2.0)            | 1 (1.1)    |
| 15–65                            | 409 (56.5) | 232 (71.8) | 193 (59.6)                         | 106 (70.2)         | 60 (66.7)  |
| >/=66                            | 289 (39.9) | 90 (27.9)   | 109 (33.6)                         | 42 (27.8)          | 29 (32.2)  |
| Data available                   | 724      | 323          | 324                                | 151                | 90         |
| Drugs (different payloads)       |          |              |                                     |                    |            |
| Tubulin polymerization inhibitors| 442 (42.0) | 203 (48.5) | 145 (35.5)                         | 78 (40.4)          | 47 (41.2)  |
| Trastuzumab emtansine            | 89 (20.1) | 19 (4.9)    | 15 (10.3)                          | 32 (41.0)          | 8 (17.0)   |
| Enfortumab vedotin               | 5 (1.1)  | 2 (1.0)      | 8 (3.5)                            | 0                  | 2 (4.3)    |
| Brentuximab vedotin              | 297 (67.3) | 157 (77.3) | 113 (78.0)                         | 36 (46.2)          | 17 (36.2)  |
| Polatuzumab vedotin              | 35 (7.9)  | 21 (10.3)   | 7 (4.8)                            | 8 (10.3)           | 15 (31.9)  |
| Belantamab mafodotin             | 16 (3.6)  | 4 (2.0)      | 2 (1.4)                            | 2 (2.5)            | 5 (10.6)   |
| DNA-damaging agents              | 612 (58.0) | 216 (51.5) | 263 (64.5)                         | 115 (59.6)         | 67 (58.8)  |
| Gemtuzumab ozogamicin            | 501 (81.9) | 186 (86.1) | 214 (81.4)                         | 85 (73.9)          | 52 (77.6)  |
| Inotuzumab ozogamicin            | 91 (14.9) | 27 (12.5)   | 49 (18.6)                          | 30 (26.1)          | 15 (22.4)  |
| Trastuzumab deruxtecan           | 6 (1.0)   | 0            | 0                                  | 0                  | 0          |
| Saccituzumab govitecan           | 14 (2.2)  | 3 (1.4)      | 0                                  | 0                  | 0          |
| Indications                      |          |              |                                     |                    |            |
| Breast cancer                    | 96 (9.1)  | 10 (2.4)     | 10 (2.5)                           | 21 (10.9)          | 0          |
| Non-Hodgkin’s lymphoma           | 0        | 0            | 0                                  | 12 (6.2)           | 0          |
| Hodgkin’s disease                | 139 (13.2) | 71 (16.9)  | 64 (15.7)                          | 21 (10.9)          | 0          |
| Diffuse large B-cell lymphoma    | 46 (4.4)  | 15 (3.6)     | 0                                  | 0                  | 0          |
| T-cell lymphoma                  | 41 (3.9)  | 11 (2.6)     | 10 (2.5)                           | 0                  | 0          |
| Anaplastic large-cell lymphoma   | 15 (1.4)  | 0            | 0                                  | 0                  | 0          |
| Acute myeloid leukemia           | 426 (40.4) | 148 (35.3) | 169 (41.4)                         | 65 (33.7)          | 38 (33.3)  |
| Acute lymphocytic leukemia       | 62 (5.9)  | 21 (5.0)     | 34 (8.3)                           | 11 (5.7)           | 0          |
| Plasma cell myeloma              | 12 (1.1)  | 0            | 0                                  | 0                  | 0          |
| Concurrent symptoms/syndromes    |          |              |                                     |                    |            |
| Sepsis                           | N/A      | 51 (12.2)    | 130 (31.9)                         | 0                  | 0          |
| Septic shock                     | 51 (4.8)  | N/A          | 102 (25.0)                         | 0                  | 0          |
| Multiple organ dysfunction syndrome| 130 (12.3) | 102 (24.3) | N/A                                | 36 (18.7)          | 0          |
| Neutropenic sepsis               | 0        | 0            | 22 (5.4)                           | N/A                | 0          |
| Bacteremia                       | 0        | 0            | 0                                  | N/A                | 0          |

(Continued on following page)
(G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF), proton pump inhibitors, H2-receptor antagonists, and CYP3A4/5 strong inhibitors. ADCs, when combined with colony-stimulating factors (G-CSF/GM-CSF), have a comparable safety signal (IC0.25 2.58 vs. 2.63) for sepsis than ADCs’ monotherapy (Table 5). We analyzed the safety profiles for the combination therapy of ADCs with PPIs or H2-receptor antagonists. Sepsis (IC0.25 2.75), septic shock (IC0.25 2.48), neutropenic sepsis (IC0.25 3.44), multiple organ dysfunction syndrome (IC0.25 3.26), pseudomonal sepsis (IC0.25 4.66), biliary sepsis (IC0.25 4.25), and streptococcal sepsis (IC0.25 3.32) were significantly associated with ADC and PPI combination therapy (Table 6). Safety concerns for sepsis (IC0.25 3.66) and septic shock (IC0.25 2.38) were detected for the combination of ADCs and H2-receptor antagonists (Table 7). We then included the most common CYP3A4/5 strong inhibitors which contain protease inhibitors, imidazole and triazole derivatives, and macrolides, and analyzed sepsis-related toxicities when ADCs were combined with the previously listed CYP3A4/5 inhibitors. We identified that risk for sepsis (ROR0.25 11.57 and IC0.25 3.06) and septic shock (ROR0.25 13.91 and IC0.25 3.95) was significantly higher for the combination than for ADC monotherapy (Table 8).

Second, we analyzed the drug–drug interaction signals for sepsis between ADCs and granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF), proton pump inhibitors, H2-receptor antagonists, and CYP3A4/5 strong inhibitors. We did not detect other drug interaction signals for sepsis-related toxicities, except for Escherichia bacteremia (Ω0.25 0.37), for the ADCs-G-CSF/GM-CSF combination. We further

### TABLE 2 (Continued) Clinical characteristics of sepsis-related toxicities correlated with ADCs.

| Characteristics                              | Sepsis   | Septic shock | Multiple organ dysfunction syndrome | Neutropenic sepsis | Bacteremia |
|----------------------------------------------|----------|--------------|-------------------------------------|--------------------|------------|
|                                             | N (%)    | N (%)        | N (%)                               | N (%)              | N (%)      |
| Other co-reported AEs                        |          |              |                                     |                    |            |
| Febrile neutropenia                          | 156 (14.8)| 50 (11.9)    | 40 (4.8)                            | 0                  | 26 (22.8)  |
| Veno-occlusive liver disease                 | 69 (6.6) | 0            | 59 (14.5)                           | 15 (7.8)           | 13 (11.4)  |
| Pneumonia                                    | 168 (15.9)| 92 (22.0)    | 0                                   | 17 (8.8)           | 0          |
| Acute respiratory distress syndrome          | 35 (3.3) | 33 (7.9)     | 0                                   | 0                  | 0          |
| Disseminated intravascular coagulation       | 34 (3.3) | 0            | 0                                   | 0                  | 0          |

ADCs, antibody–drug conjugates; N/A, not applicable; AEs, adverse events.

### TABLE 3 Time-to-onset analysis of ADC-induced sepsis and related toxicities in the FAERS database.

| Adverse event                              | Case (N) | α (95% CI)     | β (95% CI)     |
|--------------------------------------------|----------|----------------|----------------|
| Sepsis                                     | 405      | 31.2 (26.8-36.2)| 0.69 (0.42-0.74)|
| Septic shock                               | 159      | 30.1 (24.0-37.6)| 0.74 (0.65-0.82)|
| Neutropenic sepsis                         | 81       | 21.0 (16.4-26.7)| 0.96 (0.81-1.11)|
| Multiple organ dysfunction syndrome        | 77       | 32.3 (22.7-45.3)| 0.69 (0.58-0.81)|
| Bacteremia                                 | 34       | 26.6 (14.3-47.8)| 0.61 (0.46-0.78)|

The Weibull distribution is a continuous probability distribution used to analyze life data, model failure times, and access product reliability, which also could be used to conduct time-to-onset in pharmacovigilance. N, we included available data which contain the event date and ADCs therapy start date. α, scale parameter, could be used to express time-to-onset duration. β, shape parameter, could be used to confirm the distribution type: early failure type (β<1), random failure type (95% CI of β include 1), and wear-out type (β>1). 95% CI, 95% credibility interval.
identified drug interaction signals for ADCs–PPIs combination therapy and found increased safety concerns for enterococcal bacteremia ($\Omega_{0.25}$ 0.34), systemic inflammatory response syndrome ($\Omega_{0.25}$ 0.09), pseudomonal sepsis ($\Omega_{0.25}$ 1.59), streptococcal sepsis ($\Omega_{0.25}$ 0.95), and biliary sepsis ($\Omega_{0.25}$ 3.24). In contrast, DDI signals were detected for sepsis ($\Omega_{0.25}$ 0.79) and bacteremia ($\Omega_{0.25}$ 0.43) when ADCs were combined with H2-receptor antagonists. DDI signals were detected for sepsis ($\Omega_{0.25}$ 0.28) and fungemia ($\Omega_{0.25}$ 0.02) for the combination of ADCs and CYP3A4/5 inhibitors (Table 9) (Supplementary Material S2).

**Sensitivity analysis**

Some confounding factors such as indications and other known drug reactions may affect the safety signals of ADC-related toxicities. We excluded diseases (autologous hematopoietic stem cell transplant, allogenic stem cell transplantation, diabetes, organ transplant, chronic obstructive pulmonary disease, alcohol abuse, indwelling catheter management, surgery, and HIV infection) as sepsis may occur preferentially in patients with these conditions. We also excluded known drug reactions of sepsis (extracted from FDA’s labels) and chose the role code as “primary suspect drug.” After adjusting for confounders, no significant change was observed in the safety signals (Table 10).

**Discussion**

To the best of our knowledge, this is the first large-scale study to identify the association between ADCs and sepsis.
Meanwhile, the first case of sepsis (Schaefer et al., 2014) correlated with brentuximab vedotin was reported in 2014, and there have been no reviews, meta-analyses, or retrospective studies focusing on the underlying association between ADCs and sepsis. This study is the first effort to systematically associate sepsis-related toxicities occurrence with ADCs and characterize a large population of affected patients. The novelty and significance of our study is summarized in three aspects:

First, we analyzed the significant association between ADCs and sepsis, and further uncovered the clinical features of ADC-related sepsis. Through disproportionality analysis of the FAERS database, we detected significantly high safety concern for sepsis and related toxicities (including septic shock, multiple organ dysfunction syndrome, neutropenic sepsis, and bacteremia) in ADCs compared to other drugs. Safety profiles for sepsis, septic shock, and multiple organ failure syndrome have consolidated in the recent years without significant fluctuations year on year. Although spontaneous reporting systems are subject to various reporting biases which may impact signal scores, in this study, signal scores remained stable across the study years. Certainly, we cannot validate this beyond the limitations of the spontaneous reporting system, but the stable safety signal may enhance the validity of the signal. The sepsis-related toxicities that correlated with ADCs not only overlapped with each other but also with other serious toxicities such as veno-occlusive liver disease. A previous study (Kim et al., 2019) showed that patients with chemotherapy-induced febrile neutropenia are vulnerable to extended-spectrum b-lactamase-producing Enterobacteriaceae infection, which is prone to cause septic shock. We also detected the overlap of febrile neutropenia with sepsis or septic shock. The time-to-onset information of ADC-related sepsis is scarce in the published literature or FDA’s drug labels. We fitted a Weibull distribution to estimate the duration between ADC administration and sepsis occurrence. The results of Weibull parameter α and β values of ADC-related sepsis suggested that sepsis, septic shock, and bacteremia occurred within a month and classified into the early failure type, while neutropenic sepsis classified into the random failure type. Clinicians should be vigilant in the early recognition and prevention of this kind of toxicity. Different ADCs are constituted of different cytotoxic payloads and targeted monoclonal antibody. A recent review (Lievano et al., 2021) indicated that key toxicities for ADCs are primarily associated with off-target effects from the payload. We found that gemtuzumab ozogamicin and inotuzumab ozogamicin presented higher safety concerns for sepsis than any other kinds of ADCs, which may indicate the role of calicheamicin in the elevated risk of sepsis than other kinds of payloads. Males showed significantly higher safety concern for sepsis than females; however, age did not correlate with ADC-related

### Table 4: Safety signals among different ADC drugs (vs. other drugs in the full database).

| Drug name                  | All AEs | Targeted AEs | ROR (95% CI)       | IC (95% CI)     |
|----------------------------|---------|--------------|-------------------|----------------|
| Gemtuzumab ozogamicin      | 4,923   | 1,389        | 28.52 (26.80–30.35) | 4.36 (4.27–4.42) |
| Inotuzumab ozogamicin      | 1,596   | 167          | 10.53 (9.22–12.01) | 3.19 (2.99–3.35)  |
| Enfortumab vedotin         | 191     | 14           | 7.80 (4.92–12.37)  | 2.63 (1.88–3.16)  |
| Trastuzumab deruxtecan     | 129     | 8            | 3.98 (1.86–8.51)   | 1.69 (0.38–2.54)  |
| Sacituzumab govitecan      | 178     | 19           | 7.84 (4.94–12.44)  | 2.64 (1.89–3.16)  |
| Brentuximab vedotin        | 7,632   | 543          | 7.33 (6.80–7.90)   | 2.75 (2.62–2.83)  |
| Polatuzumab vedotin        | 1,196   | 114          | 8.30 (6.92–9.95)   | 2.88 (2.59–3.09)  |
| Belantamab mafodotin       | 457     | 24           | 3.05 (2.15–4.32)   | 1.53 (0.95–1.94)  |
| Trastuzumab emtansine      | 4,841   | 106          | 2.65 (2.33–3.01)   | 1.37 (1.15–1.52)  |

ADCs, antibody–drug conjugates; AEs, adverse events; IC, information component; and ROR, reporting odds ratio. 95% CI, 95% credibility interval.
sepsis. We noticed that the first case of sepsis associated with ADCs is male (Schaefer et al., 2014), and another pharmacovigilance study related to cutaneous toxicity associated with enfortumab vedotin (Yang et al., 2021) indicated that most cases were male (76.42%). This is in line with our study. But another study (Li et al., 2022) focusing on arrhythmia association with antibody–drug conjugates showed that gender differences among affected patients are not significant (female vs. male = 43.57 vs. 42.86%). The aforementioned result showed that gender difference is not the same in different adverse events of ADCs. The International Conference on Harmonization considers older people a “special population” as they differ from younger adults in terms of comorbidity, polypharmacy, pharmacokinetics, and greater vulnerability to adverse drug reactions (Davies and O’Mahony, 2015). However, another research study (Begaud et al., 2002) analyzed 92,043 spontaneous domestic reports in the French pharmacovigilance database and argued the main factor for the risk of adverse drug reaction is the number of drug

FIGURE 6
ROR of sepsis-related toxicities when males vs. females. This forest plot showed that sepsis, septic shock, bacteremia, neutropenic sepsis, staphylococcal sepsis, and multiple organ dysfunction syndrome were significantly more reported with males. This may provide alert of sepsis for clinicians when they are using ADC therapies to treat male cancer patients.

FIGURE 7
Sepsis-related toxicities landscape among ADCs and other anticancer therapies (vs. global control). The heatmap represents a comparative analysis of differential risk profiles of sepsis and related AEs across cancer drug regimens, such as Ch-chemotherapy, ADC-antibody–drug conjugates, Ta-targeted therapy, Ic-immunotherapy, HO-endocrine therapy, Im-immunomodulatory drugs, and C+T-chemotherapy combined with targeted therapy. These regimens were extracted from guidelines of FDA-approved indications for ADCs. For the more conservative global controls, we selected cancer patients not on any of the aforementioned cancer regimens, that is, patients not taking Ic, Ta, Ch, Ic+Ta, Ch+Ic, and Ch+Ta. The red color indicates a high risk of adverse effect in different cancer drug regimens. This analysis demonstrated ADCs had the highest safety concern for sepsis, multiple organ dysfunction syndrome, pseudomonal sepsis, fungemia, and blood culture positive than any other cancer drug regimens (p <0.05).
FIGURE 8
Sepsis-related toxicities landscape among ADCs and other anticancer therapies (vs. in-class control). In-class control represented other cancer patients not on a specific drug class, for instance, the controls for the Ic group were cancer patients not on Ic therapy. Similarly, controls for Ta were cancer patients not taking any targeted therapy. The red color indicates a high risk of adverse effect in different cancer drug regimens. This analysis using another control group confirmed the findings in Figure 7 that ADCs had the highest safety concern for sepsis, multiple organ dysfunction syndrome, pseudomonal sepsis, fungemia, and blood culture positive among any other cancer drug regimens (p < 0.05).

TABLE 5 Safety signals for sepsis-related toxicities reported with ADCs and colony-stimulating factors (G-CSF/GM-CSF) combination therapy vs. the full FAERS database.

| Overall AEs of ADCs+G-CSF/GM-CSF | Full database | ROR<sub>0.25</sub> | IC<sub>0.25</sub> |
|----------------------------------|---------------|------------------|----------------|
| Total number of ICSRs available  | 1914          | 16,849,672       | 6.65           | 2.58 |
| Number of ICSRs by sepsis-related AE subgroups | | | | |
| Sepsis                           | 96            | 108277           |                 |     |
| Multiple organ dysfunction syndrome | 41           | 17778            | 15.24           | 3.52 |
| Septic shock                     | 56            | 38950            | 9.98            | 3.08 |
| Neutropenic sepsis               | 36            | 7238             | 32.21           | 4.23 |

ADCs, antibody–drug conjugates; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; and AEs, adverse events.

TABLE 6 Sepsis safety signals for ADCs and proton pump inhibitors combination therapy.

| Overall AEs of ADCs+proton pump inhibitors | Full database | ROR<sub>0.25</sub> | IC<sub>0.25</sub> |
|-------------------------------------------|---------------|------------------|----------------|
| Total number of ICSRs available          | 3798          | 16,849,672       | 7.34           | 2.75 |
| Number of ICSRs by sepsis-related AE subgroups | | | | |
| Sepsis                                    | 197           | 1,08277          | 6.20           | 2.48 |
| Septic shock                              | 68            | 38,950           | 25.05          | 3.44 |
| Neutropenic sepsis                        | 34            | 7,238            | 11.36          | 3.26 |
| Multiple organ dysfunction syndrome       | 58            | 17,778           | 62.36          | 4.66 |
| Pseudomonal sepsis                        | 33            | 1,708            | 122.30         | 4.25 |
| Biliary sepsis                            | 19            | 456              | 30.04          | 3.32 |
| Streptococcal sepsis                      | 14            | 1,238            |                |     |
TABLE 7 Sepsis safety signals for ADC and H2-receptor antagonists combination therapy.

| Overall AEs of ADCs+H2-receptor antagonists | Full database | ROR_{0.25} | IC_{0.25} |
|--------------------------------------------|---------------|-------------|-----------|
| Total number of ICSRs available           | 1251          | 16,849,672  | 15.11     | 3.66      |
| Number of ICSRs by sepsis-related AE subgroups |               |             |           |           |
| Sepsis                                    | 131           | 108277      |           |           |
| Septic shock                              | 27            | 38950       | 6.51      | 2.38      |

TABLE 8 Sepsis safety signals for ADCs and CYP3A4/5 strong inhibitors combination therapy.

| Overall AEs of ADCs + CYP3A4/5 inhibitors | Full database | ROR_{0.25} | IC_{0.25} |
|------------------------------------------|---------------|-------------|-----------|
| Total number of ICSRs available         | 341           | 16,849,672  | 11.57     | 3.06      |
| Number of ICSRs by sepsis-related AE subgroups |               |             |           |           |
| Sepsis                                   | 33            | 108277      |           |           |
| Septic shock                             | 17            | 38950       | 13.91     | 3.95      |

CYP3A4/5 strong inhibitors; we included protease inhibitors, imidazole and triazole derivatives, and macrolides in this study.

TABLE 9 Drug–drug interaction analysis for ADCs and other drugs.

| Drug 1          | Drug 2                        | Adverse effect               | Ω_{0.25} |
|-----------------|--------------------------------|------------------------------|----------|
| ADCs            | Colony-stimulating factors    | *Escherichia* bacteremia     | 0.37     |
| ADCs            | Proton pump inhibitors        | *Enterococcal* bacteremia    | 0.34     |
| ADCs            | Proton pump inhibitors        | Systemic inflammatory response syndrome | 0.09 |
| ADCs            | Proton pump inhibitors        | *Pseudomonal* sepsis         | 1.59     |
| ADCs            | Proton pump inhibitors        | *Streptococcal* sepsis       | 0.95     |
| ADCs            | Proton pump inhibitors        | Biliary sepsis              | 3.24     |
| ADCs            | H2-receptor antagonists       | Sepsis                       | 0.79     |
| ADCs            | H2-receptor antagonists       | Bacteremia                   | 0.43     |
| ADCs            | H2-receptor antagonists       | *Streptococcal* bacteremia   | 0.09     |
| ADCs            | H2-receptor antagonists       | Procalciton increased        | 0.41     |
| ADCs            | H2-receptor antagonists       | *Serratia* sepsis            | 1.59     |
| ADCs            | H2-receptor antagonists       | *Salmonella* bacteremia      | 1.05     |
| ADCs            | CYP3A4/5 strong inhibitors    | Sepsis                       | 0.28     |
| ADCs            | CYP3A4/5 strong inhibitors    | Fungemia                     | 0.02     |

Ω_{0.25}, the lower limit of the 95% credibility interval of shrinkage observed-to-expected ratio. When Ω_{0.25} > 0, a significant drug–drug interaction signal was detected.

treatments and not the age itself. Further research needs to be conducted to explore the influence of gender and age on the risk of ADC-related sepsis. We identified that 766 of 2613 (29.3%) cases who developed ADC-related sepsis or related toxicity died during therapy, which reflected a disproportional mortal rate.

Second, we identified a significantly high safety concern of sepsis and multiple organ dysfunction syndrome associated with ADCs compared to other anticancer drug therapies within FDA-approved indications for ADCs. We have not found guidelines related to toxicity management of ADCs. The FDA’s drug labels that indicate serious infections and opportunistic infections are likely adverse reactions of brentuximab vedotin. No sepsis-related toxicities were mentioned in ADCs’ labels. In contrast, our pharmacovigilance study indicates that ADCs present the strongest safety concern for sepsis and multiple organ dysfunction syndrome among all included anticancer therapies, except for ADCs combined with chemotherapy.

Third, we detected drug interaction signals and found an increased risk of sepsis when ADCs were co-administrated with colony-stimulating factors, proton pump inhibitors, H2-receptor...
antagonists, and CYP3A4/5 strong inhibitors. A previous meta-analysis (Bo et al., 2011) indicated that there is no current evidence supporting the routine use of G-CSF or GM-CSF in patients with sepsis, and G-CSF or GM-CSF could not increase the reversal rate from infection in patients with sepsis. Our pharmacovigilance analysis also detected significant risk of sepsis in cancer patients who received ADCs and colony-stimulating factors (G-CSF/GM-CSF) (IC025=2.58), which further confirmed that G-CSF or GM-CSF could not increase the reversal rate from infection in patients with sepsis when co-administered with ADCs. We also detected DDI signals between ADCs and gastric medications, such as proton pump inhibitors and H2-receptor antagonists, for several subtypes of sepsis. Since most of the ADCs are metabolized by the CYP3A4/5 enzyme, the safety signal for sepsis was elevated when ADCs were co-administered with CYP3A4/5 strong inhibitors. This result demonstrates that physicians need to be vigilant when ADCs are co-administered with the aforementioned medications.

In summary, we detected a significant safety concern for ADC-related sepsis in cancer patients. The clinical features and drug interaction signals were explored. Further studies are warranted to describe underlying mechanisms and develop preventive measures of ADC-related sepsis.

**Limitations**

There are several limitations to this study. First, adverse event reports come from heterogeneous sources, which raise the possibility of incomplete information. Second, detailed clinical information is unavailable from the FAERS database, thus limiting our quality assessment to those reports. Third, we could not definitively confirm the incidence of events using spontaneous reporting systems but only for hypotheses generation. Fourth, we could not combine data from randomized controlled trials with the FAERS database because sepsis cases are rare in ADCs’ trials. Fifth, in the time-to-onset analysis, the Weibull distribution does not incorporate the effects of concomitant medications. Sixth, underreporting bias is an intrinsic limitation in research using a spontaneous database. Our time trends analysis for IC and credibility intervals in Figure 1 show some peaks and small differences through time, which can be partially explained by differences in reporting rates. However, cases in the FAERS database cover many countries in the world, thus ensuring an unparalleled global assessment of ADC-related sepsis in diverse real-world clinical settings.

**Conclusion**

Antibody–drug conjugates are promising and cutting-edge anticancer therapies which significantly improve the refractory tumor response and render patients with increased survival. However, severe sepsis-related toxicities are significantly associated with ADCs compared to other common cancer drug therapies. Patients on gemtuzumab ozogamicin and inotuzumab ozogamicin are more prone to develop sepsis than with other ADCs. In this study, males showed a significantly higher safety concern for sepsis than females, while age did not influence the safety signal of ADC-related sepsis. We identified that 766 of 2,613 (29.3%) patients who developed ADC-related sepsis died during treatment. Sepsis,
septic shock, multiple organ dysfunction syndrome, and bacteremia tend to occur in the early stage after ADCs’ administration (within a month). G-CSF/GM-CSF, proton pump inhibitors, H2-receptor antagonists, and CYP3A4/5 inhibitors may synergistically increase the risk of sepsis with ADCs. Further studies need to be conducted to uncover the mechanism of sepsis correlated with ADCs. Physicians should be aware of the safety concern of sepsis, and take early recognition and prevention measures when they are treating cancer patients with ADCs.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material; further inquiries can be directed to the corresponding author.

Author contributions

SX: formal analysis, data curation, writing—original draft, review and editing, and visualization. MS and YN: software, methodology, and writing—review and editing. LG, Y-CZ, and RM: resources. HG and Y-KW: software. B-KZ and YS: methodology and supervision. MY: conceptualization and methodology. All authors participated in the interpretation of the results. The final manuscript was read, checked, and approved by all authors.

Funding

This study was supported by the Health Commission of Hunan Province with a fund number [202113012480].

Acknowledgments

We thank MS and his team as they developed AERSMine; without this great tool to visit curated FAERS dataset, this study would not have been possible. We appreciate the help of Mohammad Ali Khaled in extracting raw data from a cleaned FAERS dataset. We thank the Hunan Provincial Department of Science and Technology for the support to the platform construction of International Research Center for Precision Medicine, Transformative Technology and Software Services, Hunan, China.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Author disclaimer

The supplied data from FAERS come from various sources. The likelihood of a causal relationship is not the same in all reports. The information does not represent the opinion of the FDA Adverse Event Reporting System.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.967017/full#supplementary-material

References

Ando, G., Taguchi, K., Enoki, Y., Yokoyama, Y., Kizu, J., and Matsumoto, K. (2019). Evaluation of the expression time of ganciclovir-induced adverse events using JADER and FAERS. Biol. Pharm. Bull. 42 (11), 1799–1804. doi:10.1248/bpb.b19-01556

Bate, A., Lindquist, M., Edwards, I. R., Olsson, S., Orre, R., Lannner, A., et al. (1998). A Bayesian neural network model for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol. 54 (4), 315–321. doi:10.1007/s002280050466

Begaud, B., Martin, K., Fourrier, A., and Haramburu, F. (2002). Does age increase the risk of adverse drug reactions? Br. J. Clin. Pharmacol. 54 (5), 550–552. doi:10.1046/j.1365-2125.2002.01649.x

Bo, L., Wang, F., Zhu, J., Li, J., and Deng, X. (2011). Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Crit. Care 15 (1), R88. doi:10.1186/cc10031

Cecconi, M., Evans, L., Levy, M., and Rhodes, A. (2018). Sepsis and septic shock. Lancet 392 (10141), 75–87. doi:10.1016/S0140-6736(18)30696-2

Chau, C. H., Steeg, P. S., and Figg, W. D. (2019). Antibody-drug conjugates for cancer. Lancet 394 (10190), 793–804. doi:10.1016/S0140-6736(19)31774-X

Criscitelli, C., Morganti, S., and Curigliano, G. (2021). Antibody-drug conjugates in solid tumors: a look into novel targets. J. Hematol. Oncol. 14 (1), 20. doi:10.1186/s13045-021-01035-z

Davies, E. A., and O’Mahony, M. S. (2015). Adverse drug reactions in special populations - the elderly. Br. J. Clin. Pharmacol. 80 (4), 796–807. doi:10.1111/bcp.12596
